Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not attend the AGM in person. The voting proxy represented 39.70% of the company’s outstanding capital.
Addex shareholders approved the 2021 annual report, the 2021 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote). All motions regarding the compensation of the board of directors and the executive management were also approved. In addition, discharge was granted to the members of the board of directors and the executive management for their activities during the business year 2021.
Addex shareholders approved the amendment of the articles of association concerning the authorized and conditional share capital of the company. The reduction of the nominal value of the issued, authorized and conditional share capital from CHF 1.00 to CHF 0.01 has also been approved and will be effective after the expiration of a period of two months following the publication in Swiss Gazette of Commerce of the third creditor call.
Dr. Vincent Lawton was re-elected as member and chairman of the board of directors and member of the compensation committee; Dr. Raymond Hill was re-elected as member of the board of directors and member of the compensation committee; and Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn and Dr. Isaac Manke were re-elected as members of the board of directors.
BDO SA were re-elected as the auditors for the 2022 business year and Robert P. Briner, attorney-at-law, was re-elected as the independent voting rights representative until the 2023 Annual General Meeting.